[go: up one dir, main page]

DK1677777T3 - Pellets indeholdende venlafaxin-hydrochlorid - Google Patents

Pellets indeholdende venlafaxin-hydrochlorid

Info

Publication number
DK1677777T3
DK1677777T3 DK04791654T DK04791654T DK1677777T3 DK 1677777 T3 DK1677777 T3 DK 1677777T3 DK 04791654 T DK04791654 T DK 04791654T DK 04791654 T DK04791654 T DK 04791654T DK 1677777 T3 DK1677777 T3 DK 1677777T3
Authority
DK
Denmark
Prior art keywords
weight
pellets
venlafaxine hydrochloride
pellets containing
chloride
Prior art date
Application number
DK04791654T
Other languages
English (en)
Inventor
Pal Fekete
Ly Tibor Korb
Eszter Moricz
Agnes Bozso
Original Assignee
Egis Gyogyszergyar Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Nyrt filed Critical Egis Gyogyszergyar Nyrt
Application granted granted Critical
Publication of DK1677777T3 publication Critical patent/DK1677777T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK04791654T 2003-10-10 2004-10-08 Pellets indeholdende venlafaxin-hydrochlorid DK1677777T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0303382A HUP0303382A2 (hu) 2003-10-10 2003-10-10 Venlafaxin-hidroklorid-tartalmú pelletek
PCT/HU2004/000095 WO2005034930A1 (en) 2003-10-10 2004-10-08 Pellets containing venlafaxine hydrochloride

Publications (1)

Publication Number Publication Date
DK1677777T3 true DK1677777T3 (da) 2007-09-03

Family

ID=90001704

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04791654T DK1677777T3 (da) 2003-10-10 2004-10-08 Pellets indeholdende venlafaxin-hydrochlorid

Country Status (22)

Country Link
EP (1) EP1677777B1 (da)
CN (1) CN1882321B (da)
AT (1) ATE359771T1 (da)
AU (1) AU2004280132B2 (da)
BG (1) BG109539A (da)
CY (1) CY1106693T1 (da)
CZ (1) CZ2006269A3 (da)
DE (1) DE602004006009T2 (da)
DK (1) DK1677777T3 (da)
EA (1) EA009695B1 (da)
ES (1) ES2285538T3 (da)
HR (2) HRP20070322T3 (da)
HU (1) HUP0303382A2 (da)
IL (1) IL174830A (da)
NO (1) NO20062082L (da)
PL (2) PL1677777T3 (da)
PT (1) PT1677777E (da)
RS (2) RS52150B (da)
SI (1) SI1677777T1 (da)
SK (1) SK50442006A3 (da)
UA (1) UA82268C2 (da)
WO (1) WO2005034930A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107213128A (zh) 1999-10-29 2017-09-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN101653411A (zh) 2000-10-30 2010-02-24 欧罗赛铁克股份有限公司 控释氢可酮制剂
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US20080193524A1 (en) * 2005-07-28 2008-08-14 Dr. Reddy's Laboratories Ltd. Extended Release Venlafaxine Compositions
EA014262B1 (ru) * 2006-05-19 2010-10-29 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Способ получения гранулированной массы
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20130171256A1 (en) * 2010-05-11 2013-07-04 Cima Labs Inc. Alcohol-resistant extended release dosage forms comprising venlafaxine
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
EA201590776A1 (ru) * 2012-12-19 2015-11-30 Ратиофарм Гмбх Пеллеты с пленочным покрытием
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术(石家庄)有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN114028577B (zh) * 2021-10-20 2024-07-02 珠海市东辰制药有限公司 一种二氧化硅丸芯及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1331003B1 (en) * 1996-03-25 2015-08-26 Wyeth LLC Extended release formulation containing venlafaxine
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
CN1334080A (zh) * 2001-07-25 2002-02-06 成都康弘制药有限公司 盐酸万拉法新缓释片及其制备方法
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US20030190351A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Extended release venlafaxine formulations

Also Published As

Publication number Publication date
CZ2006269A3 (cs) 2006-07-12
HRP20070322T3 (hr) 2007-09-30
ATE359771T1 (de) 2007-05-15
EA200600675A1 (ru) 2006-08-25
SK50442006A3 (sk) 2006-08-03
HUP0303382D0 (en) 2003-12-29
PL379541A1 (pl) 2006-10-02
HUP0303382A2 (hu) 2005-08-29
IL174830A (en) 2010-04-15
WO2005034930A1 (en) 2005-04-21
AU2004280132A1 (en) 2005-04-21
ES2285538T3 (es) 2007-11-16
AU2004280132B2 (en) 2009-10-22
DE602004006009T2 (de) 2008-01-10
PT1677777E (pt) 2007-06-21
CY1106693T1 (el) 2012-05-23
EA009695B1 (ru) 2008-02-28
EP1677777A1 (en) 2006-07-12
HRP20060136A2 (en) 2006-06-30
SI1677777T1 (sl) 2007-10-31
CN1882321B (zh) 2011-06-08
CN1882321A (zh) 2006-12-20
RS52150B (sr) 2012-08-31
DE602004006009D1 (de) 2007-05-31
EP1677777B1 (en) 2007-04-18
RS20060252A (sr) 2008-08-07
NO20062082L (no) 2006-05-09
UA82268C2 (uk) 2008-03-25
PL1677777T3 (pl) 2007-08-31
IL174830A0 (en) 2008-04-13
BG109539A (bg) 2006-11-30
HK1098364A1 (en) 2007-07-20

Similar Documents

Publication Publication Date Title
DK1677777T3 (da) Pellets indeholdende venlafaxin-hydrochlorid
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
MY144477A (en) Galenic formulations of organic compounds
WO2009028495A1 (ja) 真菌性皮膚炎用剤
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
JP2008013542A5 (da)
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
HRP20100120T1 (hr) Formulacije s valsartanom
DK1711169T3 (da) Coatede mikrodepottabletter med venlafaxinhydrochlorid
EA201170784A1 (ru) Гранулы тамсулозина для фиксированной комбинации
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
CA3244360A1 (en) Compositions containing MEAI and N-acylethanolamines and their uses
TW200800977A (en) A new salt
EA200702496A1 (ru) Местная композиция, содержащая желатин
EA200500175A1 (ru) Соль морфин-6-глюкуронида
PL1589014T3 (pl) Sposób syntezy pochodnych 1,3-dihydro-2H-3-benzazepin-2-onu i jego zastosowanie do wytwarzania iwabradyny i jej dopuszczalnych farmaceutycznie soli
SG170037A1 (en) Compositions useful for reducing nephrotoxicity and methods of use thereof
RU2015129081A (ru) Гелевые композиции
HUP0303383A2 (hu) Piridazinon-származékot tartalmazó pelletek
GR1004331B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
UA115684C2 (uk) Фармацевтична композиція для перорального застосування, що містить декскетопрофен та трамадол
TW200631600A (en) Hair fitness/body improving agent and hair cosmetic